Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Autor: Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso Guerra, Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell, Alan Haycox

Publikováno v: Frontiers in Public Health, Vol 6 (2018)

Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices alon

Externí odkaz: https://doaj.org/article/44e09c6a8ab54400ba7f5f970ab42861

Payers’ views of the changes arising through the possible adoption of Adaptive Pathways

Autor: Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, Francis Arickx, Alexander Bybau, Tomasz Bochenek, Marc Van De Casteele, Eduardo Diogene, Jurij Furst, Kristina Garuoliene, Martin van der Graaff, Jolanta Gulbinovic, Alan Haycox, Jan Jones, Roberta Joppi, Ott Laius, Irene Langner, Anthony Martin, Vanda Markovic-Pekovic, Laura McCullagh, Einar Magnusson, Ellen Nilsen, Gisbert Selke, Catherine Sermet, Steven Simoens, Robert Sauermann, Ad Schuurman, Ricardo Ramos, Vera Vlahovic-Palcevski, Corinne Zara, Brian Godman

Publikováno v: Frontiers in Pharmacology, Vol 7 (2016)

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further

Externí odkaz: https://doaj.org/article/40d4ad711a0845b293f34d8201689534

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Autor: Szczepan Jakubowski, Przemysław Holko, Rafał Nowak, Marisa Warmuth, Marc Dooms, Outi Salminen, Lucas Cortial, Gisbert W. Selke, Christina Georgi, Einar Magnússon, Salvatore Crisafulli, Fons Strijbosch, Tanja Mueller, Eleanor Grieve, Immaculada Danés, Paweł Kawalec

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

ObjectivesThe aim of the study was to assess the reimbursement policy for orphan drugs (ODs) in selected European countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedures and reimburseme

Externí odkaz: https://doaj.org/article/a9f7b56e86894d9dbed9b0cc589817a1

Proposal for a Regulation on Health Technology Assessment in Europe - opinions of policy makers, payers and academics from the field of HTA

Autor: Magdalene Wladysiuk, Claudia Furtado, Patricia Vella Bonanno, Alan Haycox, Robert Sauermann, Brian Godman, Tomasz Bochenek, Merce Obach Cortadellas, Steven Simoens, Maria Dimitrova, Jurij Fürst, Wija Oortwijn, Guenka Petrova, Dmitry Meshkov, Stephen Campbell, Ott Laius, Maria Kamusheva, Corrine Zara, Roberta Joppi, John Yfantopoulos, Celia C. Rothe, Vanda Marković-Peković, Angela Timoney, Einar Magnusson, Ahmed Salem, Gisbert Selke, D Tomek, Antony P. Martin, Alessandra Ferrario, Jolanta Gulbinovič, Iris Hoxha, Anna Bucsics, Mohamed Gad, Ileana Mardare, Vasilios Kourafalos, Arianit Jakupi

Publikováno v: Expert Review of Pharmacoeconomics and Outcomes Research, 19, 3, pp. 251-261
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Expert Review of Pharmacoeconomics and Outcomes Research, 19, 251-261
J R Soc Med

Contains fulltext : 203380.pdf (Publisher’s version ) (Closed access) INTRODUCTION: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cad623c49948c7e6f53d77706c5415b
https://ruj.uj.edu.pl/xmlui/handle/item/118555

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future

Autor: Stuart McTaggart, Kristina Garuoliene, Jurij Fürst, Scott M Bryson, Andrew Martin, Winne de Bruyn, Antra Fogele, Agnes Vitry, Hanne Bak Pedersen, Catherine Sermet, Gisbert Selke, Anne Marthe Ringerud, Krijn Schiffers, Eva Andersén Karlsson, Michael Wilcock, Anita Viksna, Irene Langner, Ljiljana Sović-Brkičić, Anna Coma Fusté, Marija Kalaba, Mikael Hoffmann, Peter Skiold, Sisira Jayathissa, Vanda Marković-Peković, Tomasz Bochenek, Einar Magnusson, Ott Laius, Christoph Baumgärtel, Scott Metcalfe, Corinne Zara, Brian Godman, D Tomek, Jutta Piessnegger, Rickard E. Malmström, Juraj Slabý, Harald Herholz, Jessica Fraeyman, Hye-Young Kwon, Marco D’Agata

Publikováno v: Generics and Biosimilars Initiative Journal. 4:125-135

The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain: its principal indication. The manufacturer has threatened legal action in the UK if generic pregabalin rather than Lyrica is prescribed for this indicat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fb38f15e5d3afb567a542ef059014b
https://doi.org/10.5639/gabij.2015.0403.028